ERBB2 and neoplasm: Furthermore, TN tumours, compared to HR+ and/or HER2+ tumours, were more at risk of distant metastases (DMFS at 53.9%; 95% CI: [43.3; 63.4] vs. 65.5%; 95% CI: [58.1; 71.8]; p = 0.0005) and locoregional recurrence (LRFS at 50.3%; 95% CI: [39.8; 60.0] vs. 80.5%; 95% CI: [74.1; 85.5]; p < 0.0001) (Figure 1).